- Details
- Description
LuciPac (Pacritinib) is a prescription medicine containing pacritinib, an oral kinase inhibitor used for the treatment of adults with certain forms of intermediate- or high-risk primary or secondary myelofibrosis, particularly in patients with severe thrombocytopenia.
Pacritinib works by inhibiting Janus kinase 2 (JAK2), interleukin-1 receptor-associated kinase 1 (IRAK1), and activin A receptor type 1 (ACVR1), signaling pathways involved in myelofibrosis and abnormal blood-cell production.
Active Ingredient: Pacritinib
Dosage Form: Oral capsule
Therapeutic Category: JAK2/IRAK1 inhibitor
Prescription Status: Prescription medicine
Treatment: Certain adults with intermediate- or high-risk myelofibrosis with severe thrombocytopenia, as prescribed by a healthcare professional.
LuciPac should be used strictly according to the prescribing physician's instructions. Treatment may require monitoring of blood counts, liver function, and other clinical parameters.
